PARP1 Inhibitor therapy(Acerand Therapeutics)

N/A

Report date: 2024/06/13 10:26:26

Base Information

Drug NamePARP1 Inhibitor therapy(Acerand Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitors
TargetsPoly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesAcerand Therapeutics (Shanghai) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAcerand Therapeutics (Shanghai) Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A